Form D · Biotechnology
CASCADE TECHNOLOGIES CORP
Beverly Hills, CA · CIK 0001324344
Offering snapshot reported Apr 26, 2010 · SEC filing
- Reported sold
- $1.15M Offering amount: $2M
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Mar 15, 2010 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 26, 2010 | Initial | $1,150,000 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Security to be acquired
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-141103
Of the 1,150,000 subscribed for, $850K has been paid and $300K remains outstanding.
Source: Form D, filed Apr 26, 2010. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jacqueline Danforth | Director, Executive |
| Daniel Farkas | Director |
| Erik Lindsley | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
250 North Robertson Blvd Suite 427
Beverly Hills, CA, 90211
Beverly Hills, CA, 90211